Il13 (interleukin 13) - Rat Genome Database

Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Gene: Il13 (interleukin 13) Rattus norvegicus
Analyze
Symbol: Il13
Name: interleukin 13
RGD ID: 68949
Description: Enables interleukin-13 receptor binding activity. Involved in several processes, including positive regulation of cell population proliferation; positive regulation of macromolecule metabolic process; and regulation of monoatomic cation transmembrane transport. Located in extracellular space. Used to study asthma; extrinsic allergic alveolitis; and lipoid nephrosis. Biomarker of several diseases, including alcoholic hepatitis; middle cerebral artery infarction; peptic esophagitis; prostatic hypertrophy; and pulmonary fibrosis. Human ortholog(s) of this gene implicated in several diseases, including allergic disease (multiple); autoimmune disease (multiple); diffuse scleroderma; lung disease (multiple); and nose disease (multiple). Orthologous to human IL13 (interleukin 13); PARTICIPATES IN Fc epsilon receptor mediated signaling pathway; asthma pathway; cytokine mediated signaling pathway; INTERACTS WITH 3-chloropropane-1,2-diol; acrylamide; ammonium chloride.
Type: protein-coding
RefSeq Status: PROVISIONAL
Previously known as: IL-13; interleukin-13; T-cell activation protein P600
RGD Orthologs
Human
Mouse
Chinchilla
Bonobo
Dog
Squirrel
Pig
Green Monkey
Naked Mole-Rat
Alliance Genes
More Info more info ...
Latest Assembly: mRatBN7.2 - mRatBN7.2 Assembly
Position:
Rat AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
mRatBN7.21037,790,130 - 37,792,687 (-)NCBImRatBN7.2mRatBN7.2
mRatBN7.2 Ensembl1037,790,130 - 37,792,737 (-)EnsemblmRatBN7.2 Ensembl
UTH_Rnor_SHR_Utx1042,482,076 - 42,484,637 (-)NCBIRnor_SHR
UTH_Rnor_SHRSP_BbbUtx_1.01041,972,140 - 41,974,701 (-)NCBIRnor_SHRSP
UTH_Rnor_WKY_Bbb_1.01037,475,862 - 37,478,423 (-)NCBIRnor_WKY
Rnor_6.01038,982,909 - 38,985,466 (-)NCBIRnor6.0Rnor_6.0rn6Rnor6.0
Rnor_6.0 Ensembl1038,982,909 - 38,985,466 (-)EnsemblRnor6.0rn6Rnor6.0
Rnor_5.01038,764,639 - 38,767,196 (-)NCBIRnor5.0Rnor_5.0rn5Rnor5.0
RGSC_v3.41039,093,512 - 39,096,069 (-)NCBIRGSC3.4RGSC_v3.4rn4RGSC3.4
RGSC_v3.11039,102,758 - 39,105,316 (-)NCBI
Celera1037,134,342 - 37,136,897 (-)NCBICelera
Cytogenetic Map10q22NCBI
JBrowse: View Region in Genome Browser (JBrowse)
Model


Disease Annotations     Click to see Annotation Detail View
Acute Lung Injury  (IEP)
alcoholic hepatitis  (IEP)
allergic conjunctivitis  (ISO)
allergic disease  (ISO)
allergic rhinitis  (ISO)
asthma  (IDA,IEP,IMP,ISO)
atopic dermatitis  (ISO)
autistic disorder  (ISO)
autoimmune hepatitis  (ISO)
Breast Neoplasms  (ISO)
Bronchial Hyperreactivity  (ISO)
bronchiolitis obliterans  (ISO)
chlamydia  (ISO)
Chronic Bronchitis  (ISO)
chronic obstructive pulmonary disease  (ISO)
contact dermatitis  (ISO)
COVID-19  (ISO)
cutaneous leishmaniasis  (ISO)
cystic fibrosis  (ISO)
Delayed Hypersensitivity  (ISO)
dermatitis  (ISO)
diffuse scleroderma  (ISO)
drug allergy  (ISO)
Eczema  (ISO)
egg allergy  (ISO)
Endotoxemia  (ISO)
esophagitis  (ISO)
Experimental Arthritis  (IMP,ISO)
Experimental Autoimmune Encephalomyelitis  (ISO)
Experimental Autoimmune Myocarditis  (IMP)
extrinsic allergic alveolitis  (IMP,ISO)
familial adenomatous polyposis 1  (ISO)
Fibrosis  (IEP)
food allergy  (ISO)
Fungal Lung Diseases  (IEP,ISO)
Graves' disease  (ISO)
hepatitis C  (ISO)
Hereditary Neoplastic Syndromes  (ISO)
Human Influenza  (ISO)
Hyperalgesia  (ISO)
Hyperplasia  (ISO)
Immediate Hypersensitivity  (ISO)
Inflammation  (ISO)
invasive ductal carcinoma  (ISO)
Kawasaki disease  (ISO)
lipoid nephrosis  (IMP)
localized scleroderma  (ISO)
lung disease  (ISO)
Lymphatic Metastasis  (ISO)
mastocytosis  (ISO)
Metaplasia  (ISO)
middle cerebral artery infarction  (IEP)
milk allergy  (ISO)
multiple sclerosis  (ISO)
Mycoplasma pneumoniae pneumonia  (ISO)
Nasal Polyps  (ISO)
Neurodevelopmental Disorders  (ISO)
non-alcoholic fatty liver disease  (ISO)
occupational dermatitis  (ISO)
onchocerciasis  (ISO)
ovarian carcinoma  (ISO)
pancreatic cancer  (ISO)
pancreatitis  (IEP,ISO)
peanut allergy  (ISO)
peptic esophagitis  (IEP)
Perennial Allergic Rhinitis  (ISO)
Picornaviridae Infections  (ISO)
Plasmodium falciparum malaria  (ISO)
pneumonia  (ISO)
prostatic hypertrophy  (IEP)
Pseudomonas Infections  (ISO)
psoriasis  (ISO)
psoriatic arthritis  (ISO)
pulmonary edema  (ISO)
pulmonary emphysema  (ISO)
pulmonary eosinophilia  (ISO)
pulmonary fibrosis  (IEP,ISO)
pulmonary hypertension  (ISO)
pulmonary tuberculosis  (ISO)
purpura  (ISO)
Radiation Pneumonitis  (ISO)
renal cell carcinoma  (ISO)
Reperfusion Injury  (IEP,ISO)
respiratory allergy  (ISO)
Respiratory Sounds  (ISO)
respiratory syncytial virus infectious disease  (ISO)
Respiratory Tract Granuloma  (ISO)
Respiratory Tract Infections  (ISO)
rheumatoid arthritis  (ISO)
rhinitis  (IEP,ISO)
Schistosomiasis Mansoni  (IMP)
Sepsis  (IEP,ISO)
sinusitis  (ISO)
Sjogren's syndrome  (ISO)
systemic lupus erythematosus  (ISO)
systemic scleroderma  (ISO)
T-Cell Lymphoma  (ISO)
Transplant Rejection  (IDA,IEP,ISO)
uveitis  (ISO)
vitiligo  (ISO)

Gene-Chemical Interaction Annotations     Click to see Annotation Detail View
(4-oxo-3-\{[5-(trifluoromethyl)-1,3-benzothiazol-2-yl]methyl\}-3,4-dihydrophthalazin-1-yl)acetic acid  (ISO)
1,1-dichloroethene  (ISO)
1,2-dichloroethane  (ISO)
1-chloro-2,4-dinitrobenzene  (ISO)
2,3,7,8-tetrachlorodibenzodioxine  (ISO)
2-tert-butylhydroquinone  (ISO)
3,3',4,4',5-pentachlorobiphenyl  (ISO)
3-chloropropane-1,2-diol  (EXP)
4,4'-diaminodiphenylmethane  (ISO)
4-tolyl isocyanate  (ISO)
9-cis-retinoic acid  (ISO)
abacavir  (ISO)
acetone  (ISO)
acetylsalicylic acid  (ISO)
acrylamide  (EXP)
all-trans-retinoic acid  (ISO)
alpha-galactosylceramide  (ISO)
aluminium hydroxide  (ISO)
ammonium chloride  (EXP)
anthra[1,9-cd]pyrazol-6(2H)-one  (ISO)
antigen  (ISO)
arsane  (ISO)
arsenic atom  (ISO)
arsenous acid  (ISO)
beclomethasone  (ISO)
benzo[a]pyrene  (ISO)
benzofurans  (ISO)
benzyl isothiocyanate  (ISO)
beta-naphthoflavone  (ISO)
bis(2-chloroethyl) sulfide  (EXP,ISO)
bisphenol A  (EXP,ISO)
bleomycin A2  (ISO)
Brevetoxin B  (ISO)
bucladesine  (ISO)
budesonide  (ISO)
butanal  (ISO)
butane-2,3-dione  (ISO)
C.I. Natural Red 20  (ISO)
cadmium atom  (ISO)
cadmium dichloride  (ISO)
Calcimycin  (EXP,ISO)
calcipotriol  (ISO)
calcitriol  (ISO)
calcium atom  (ISO)
calcium(0)  (ISO)
cannabidiol  (ISO)
capsaicin  (EXP)
carbon monoxide  (ISO)
carbon nanotube  (ISO)
ceric oxide  (ISO)
chlorobenzene  (ISO)
chloroform  (ISO)
chloroquine  (ISO)
chlorpyrifos  (ISO)
choline  (ISO)
clopidogrel  (ISO)
colforsin daropate hydrochloride  (ISO)
copper atom  (EXP)
copper(0)  (EXP)
crocidolite asbestos  (ISO)
D-penicillamine  (EXP)
deguelin  (ISO)
deoxynivalenol  (ISO)
dexamethasone  (EXP,ISO)
diarsenic trioxide  (ISO)
dichlorine  (ISO)
dicyclohexylmethane-4,4'-diisocyanate  (ISO)
diisononyl phthalate  (ISO)
dioscin  (ISO)
diphenylmethane-4,4'-diisocyanate  (ISO)
donepezil hydrochloride  (ISO)
emodin  (ISO)
epinastine  (ISO)
etazolate  (ISO)
ethambutol  (ISO)
ethene  (EXP)
Fidarestat  (ISO)
fisetin  (ISO)
formaldehyde  (EXP,ISO)
formoterol fumarate  (EXP)
fragrance  (ISO)
gadodiamide hydrate  (ISO)
gadolinium trichloride  (ISO)
genistein  (EXP)
gentamycin  (EXP)
glutathione  (ISO)
glyphosate  (ISO)
graphite  (ISO)
hexamethylene diisocyanate  (ISO)
hydrogen peroxide  (ISO)
hydroxyurea  (ISO)
ilomastat  (EXP)
ionomycin  (ISO)
isophorone diisocyanate  (ISO)
lactacystin  (ISO)
lead diacetate  (ISO)
lead(0)  (ISO)
lead(2+)  (ISO)
leflunomide  (ISO)
leukotriene B4  (EXP)
leukotriene C4  (EXP,ISO)
leukotriene D4  (EXP)
leukotriene E4  (EXP)
lidocaine  (ISO)
linuron  (ISO)
lipopolysaccharide  (EXP,ISO)
lipoxin A4  (ISO)
luteolin  (EXP)
mercury dichloride  (ISO)
metformin  (ISO)
methotrexate  (ISO)
methoxychlor  (EXP,ISO)
MK 571  (EXP,ISO)
montelukast  (ISO)
morphine  (ISO)
mycophenolic acid  (ISO)
mycotoxin  (ISO)
N-acetyl-L-cysteine  (ISO)
N-ethyl-5'-carboxamidoadenosine  (ISO)
N-methyl-4-phenylpyridinium  (ISO)
N-nitrosodiethylamine  (EXP,ISO)
naproxen  (EXP)
nickel atom  (ISO)
nickel dichloride  (ISO)
nitrogen dioxide  (ISO)
nitrososulfamethoxazole  (ISO)
ochratoxin A  (ISO)
organophosphorus compound  (ISO)
ozone  (EXP,ISO)
paracetamol  (ISO)
paraquat  (EXP,ISO)
parathion  (ISO)
patulin  (ISO)
phenobarbital  (EXP)
phorbol 13-acetate 12-myristate  (ISO)
phosmet  (ISO)
phthalaldehyde  (ISO)
phthalic anhydride  (ISO)
pioglitazone  (ISO)
piperonyl butoxide  (ISO)
polymyxin B2  (ISO)
pomalidomide  (ISO)
prednisolone  (ISO)
prednisone  (ISO)
pregnenolone 16alpha-carbonitrile  (EXP)
prostaglandin E2  (ISO)
pyocyanine  (ISO)
quercetin  (ISO)
resveratrol  (EXP,ISO)
rifampicin  (ISO)
rolipram  (ISO)
ruxolitinib  (ISO)
serotonin  (ISO)
serpentine asbestos  (ISO)
Shikonin  (ISO)
silicon dioxide  (ISO)
simvastatin  (ISO)
sodium arsenite  (ISO)
sterigmatocystin  (ISO)
sulfur dioxide  (ISO)
sumatriptan  (EXP)
sunitinib  (ISO)
syringin  (ISO)
Terfenadine  (ISO)
tetrachloromethane  (ISO)
theophylline  (ISO)
thimerosal  (ISO)
thioacetamide  (ISO)
titanium dioxide  (ISO)
toluene 2,4-diisocyanate  (ISO)
tributylstannane  (EXP)
Tributyltin oxide  (EXP)
triclosan  (ISO)
trimellitic anhydride  (ISO)
valproic acid  (ISO)
zearalenone  (ISO)
zileuton  (EXP,ISO)

Gene Ontology Annotations     Click to see Annotation Detail View

Biological Process
cellular response to cytokine stimulus  (ISO)
cellular response to mechanical stimulus  (IEP)
immune response  (IEA)
inflammatory response  (ISO)
macrophage activation  (ISO)
microglial cell activation  (IMP)
negative regulation of complement-dependent cytotoxicity  (ISO)
negative regulation of endothelial cell apoptotic process  (ISO)
negative regulation of inflammatory response  (ISO)
negative regulation of NAD(P)H oxidase activity  (IMP)
negative regulation of neuron death  (IMP)
negative regulation of transforming growth factor beta production  (IDA)
positive regulation of B cell proliferation  (IDA)
positive regulation of cold-induced thermogenesis  (ISO,ISS)
positive regulation of connective tissue growth factor production  (IDA)
positive regulation of gene expression  (IDA,ISO)
positive regulation of immunoglobulin production  (IDA,ISO)
positive regulation of interleukin-10 production  (ISO)
positive regulation of macrophage activation  (ISO)
positive regulation of mast cell degranulation  (ISO)
positive regulation of monoatomic ion transport  (IDA)
positive regulation of pancreatic stellate cell proliferation  (IDA)
positive regulation of protein secretion  (IDA)
positive regulation of release of sequestered calcium ion into cytosol  (IDA)
positive regulation of smooth muscle cell proliferation  (IDA)
positive regulation of tyrosine phosphorylation of STAT protein  (IDA)
regulation of proton transport  (IDA)
response to ethanol  (IEP)
response to lipopolysaccharide  (IEP)
response to mechanical stimulus  (IEP)
response to nicotine  (IDA)
signal transduction  (IEA)

Cellular Component

Molecular Function

Molecular Pathway Annotations     Click to see Annotation Detail View
References

References - curated
# Reference Title Reference Citation
1. Essential role of NKT cells producing IL-4 and IL-13 in the development of allergen-induced airway hyperreactivity. Akbari O, etal., Nat Med. 2003 May;9(5):582-8. Epub 2003 Mar 31.
2. Effects of allergic airway disease on mouse adenovirus type 1 respiratory infection. Anderson VE, etal., Virology. 2009 Aug 15;391(1):25-32. Epub 2009 Jun 28.
3. Cytokine production, activation marker, and skin homing receptor in children with atopic dermatitis and bronchial asthma. Antunez C, etal., Pediatr Allergy Immunol. 2006 May;17(3):166-74.
4. Polymorphisms in the interleukin 13 and GATA binding protein 3 genes and the development of eczema during childhood. Arshad SH, etal., Br J Dermatol. 2008 Jun;158(6):1315-22. doi: 10.1111/j.1365-2133.2008.08565.x. Epub 2008 Apr 10.
5. Breast cancer instructs dendritic cells to prime interleukin 13-secreting CD4+ T cells that facilitate tumor development. Aspord C, etal., J Exp Med. 2007 May 14;204(5):1037-47. Epub 2007 Apr 16.
6. Interleukin-13 promotes susceptibility to chlamydial infection of the respiratory and genital tracts. Asquith KL, etal., PLoS Pathog. 2011 May;7(5):e1001339. Epub 2011 May 5.
7. Proinflammatory and regulatory cytokines and chemokines in infants with uncomplicated and severe Plasmodium falciparum malaria. Ayimba E, etal., Clin Exp Immunol. 2011 Nov;166(2):218-26. doi: 10.1111/j.1365-2249.2011.04474.x.
8. Ethnicity-specific gene-gene interaction between IL-13 and IL-4Ralpha among African Americans with asthma. Battle NC, etal., Am J Respir Crit Care Med. 2007 May 1;175(9):881-7. Epub 2007 Feb 15.
9. Polymorphisms in IL13 pathway genes in asthma and chronic obstructive pulmonary disease. Beghe B, etal., Allergy. 2010 Apr;65(4):474-81. Epub 2009 Oct 1.
10. Th1 and Th17 hypercytokinemia as early host response signature in severe pandemic influenza. Bermejo-Martin JF, etal., Crit Care. 2009;13(6):R201. Epub 2009 Dec 11.
11. Increased hyperoxia-induced mortality and acute lung injury in IL-13 null mice. Bhandari V, etal., J Immunol. 2007 Apr 15;178(8):4993-5000.
12. Pharmacological assessment of the nitric-oxide synthase isoform involved in eosinophilic inflammation in a rat model of sephadex-induced airway inflammation. Birrell MA, etal., J Pharmacol Exp Ther. 2003 Mar;304(3):1285-91.
13. Interleukin 13 and interleukin 4 receptor-alpha polymorphisms in rhinitis and asthma. Bottema RW, etal., Int Arch Allergy Immunol. 2010;153(3):259-67. Epub 2010 May 19.
14. Evidence to support IL-13 as a risk locus for psoriatic arthritis but not psoriasis vulgaris. Bowes J, etal., Ann Rheum Dis. 2011 Jun;70(6):1016-9. doi: 10.1136/ard.2010.143123. Epub 2011 Feb 23.
15. Polymorphisms in the interleukin 4, interleukin 13, and corresponding receptor genes are not associated with systemic sclerosis and do not influence gene expression. Broen JC, etal., J Rheumatol. 2012 Jan;39(1):112-8. doi: 10.3899/jrheum.110235. Epub 2011 Nov 1.
16. Protective effect of Ulinastatin against murine models of sepsis: inhibition of TNF-alpha and IL-6 and augmentation of IL-10 and IL-13. Cao YZ, etal., Exp Toxicol Pathol. 2012 Sep;64(6):543-7. doi: 10.1016/j.etp.2010.11.011. Epub 2010 Dec 14.
17. Macrophage-inactivating IL-13 suppresses experimental autoimmune encephalomyelitis in rats. Cash E, etal., J Immunol. 1994 Nov 1;153(9):4258-67.
18. IL-13 is required for eosinophil entry into the lung during respiratory syncytial virus vaccine-enhanced disease. Castilow EM, etal., J Immunol. 2008 Feb 15;180(4):2376-84.
19. Interleukin-13 and IgE production in rat experimental schistosomiasis. Cetre C, etal., Eur Cytokine Netw. 2000 Jun;11(2):241-49.
20. Association between non-atopic hand eczema and interleukin-13 gene polymorphism in Taiwanese nursing population. Chen YC, etal., Exp Dermatol. 2012 Dec;21(12):972-4. doi: 10.1111/exd.12045.
21. Interferon and alternative activation of monocyte/macrophages in systemic sclerosis-associated pulmonary arterial hypertension. Christmann RB, etal., Arthritis Rheum. 2011 Jun;63(6):1718-28. doi: 10.1002/art.30318.
22. Roflumilast, a phosphodiesterase 4 inhibitor, alleviates bleomycin-induced lung injury. Cortijo J, etal., Br J Pharmacol. 2009 Feb;156(3):534-44.
23. IL-13 prolongs allograft survival: association with inhibition of macrophage cytokine activation. Davidson C, etal., Transpl Immunol. 2007 Apr;17(3):178-86. Epub 2006 Nov 3.
24. Protein kinase Czeta (PKCzeta) regulates ocular inflammation and apoptosis in endotoxin-induced uveitis (EIU): signaling molecules involved in EIU resolution by PKCzeta inhibitor and interleukin-13. de Kozak Y, etal., Am J Pathol. 2007 Apr;170(4):1241-57.
25. IL-13 from Th2-type cells suppresses induction of antigen-specific Th1 immunity in a T-cell lymphoma. Deepak P, etal., Int Immunol. 2010 Jan;22(1):53-63. doi: 10.1093/intimm/dxp114. Epub 2009 Nov 30.
26. [Association of interleukin-13 gene polymorphisms with atopic bronchial asthma] Dmitrieva-Zdorova EV, etal., Genetika. 2010 Jan;46(1):111-7.
27. Association between IL13 polymorphisms and psoriatic arthritis is modified by smoking. Duffin KC, etal., J Invest Dermatol. 2009 Dec;129(12):2777-83. doi: 10.1038/jid.2009.169. Epub 2009 Jun 25.
28. Ultrastructural and immunological features of experimental cutaneous leishmaniasis after treatment with intralesional hypertonic sodium chloride and CO2 laser rays. Eissa MM, etal., J Egypt Soc Parasitol. 2003 Apr;33(1):329-52.
29. The effect of hydrodynamics-based delivery of an IL-13-Ig fusion gene for experimental autoimmune myocarditis in rats and its possible mechanism. Elnaggar R, etal., Eur J Immunol. 2005 Jun;35(6):1995-2005.
30. Interleukin13 haplotypes and susceptibility of Iranian women to breast cancer. Faghih Z, etal., Mol Biol Rep. 2009 Sep;36(7):1923-8. doi: 10.1007/s11033-008-9400-7. Epub 2008 Nov 7.
31. Genetic variants of the genes encoding zinc finger protein 313 and interleukin-13 confer a risk for psoriasis in a Chinese Uygur population. Feng YY, etal., Clin Exp Dermatol. 2013 Oct;38(7):768-74. Epub 2013 Mar 21.
32. T helper-2 immunity regulates bronchial hyperresponsiveness in eosinophil-associated gastrointestinal disease in mice. Forbes E, etal., Gastroenterology. 2004 Jul;127(1):105-18.
33. Interleukin-13 exerts autocrine growth-promoting effects on human pancreatic cancer, and its expression correlates with a propensity for lymph node metastases. Formentini A, etal., Int J Colorectal Dis. 2009 Jan;24(1):57-67. Epub 2008 Aug 31.
34. Spatial and temporal expression of CCR3 and the common beta chain of the IL-3, IL-5 and GM-CSF receptor in the nasal epithelium and lymphoid tissues in a rat model of allergic rhinitis. Fortin M, etal., Cytokine. 2010 Aug 7.
35. Characterization of cytokine mRNA transcripts in conjunctival cells in patients with allergic conjunctivitis. Fujishima H, etal., Invest Ophthalmol Vis Sci. 1997 Jun;38(7):1350-7.
36. Promoting effects of IL-13 on Ca2+ release and store-operated Ca2+ entry in airway smooth muscle cells. Gao YD, etal., Pulm Pharmacol Ther. 2010 Jun;23(3):182-9. Epub 2010 Jan 4.
37. Interleukin-13 promoter gene polymorphism -1112 C/T is associated with atopic dermatitis in Polish patients. Glen J, etal., Acta Dermatovenerol Croat. 2012 Dec;20(4):231-8.
38. Rat ISS GO annotations from GOA human gene data--August 2006 GOA data from the GO Consortium
39. Phenotypic and functional changes of cytotoxic CD56pos natural T cells determine outcome of acute hepatitis C virus infection. Golden-Mason L, etal., J Virol. 2007 Sep;81(17):9292-8. doi: 10.1128/JVI.00834-07. Epub 2007 Jun 6.
40. Enhanced allergic inflammation and airway responsiveness in rats with chronic Cryptococcus neoformans infection: potential role for fungal pulmonary infection in the pathogenesis of asthma. Goldman DL, etal., J Infect Dis. 2006 Apr 15;193(8):1178-86. Epub 2006 Mar 9.
41. Plasma cytokine profiles in systemic sclerosis: associations with autoantibody subsets and clinical manifestations. Gourh P, etal., Arthritis Res Ther. 2009;11(5):R147. Epub 2009 Oct 2.
42. Evaluation of interleukin 13 polymorphisms in systemic sclerosis. Granel B, etal., Immunogenetics. 2006 Aug;58(8):693-9. Epub 2006 Jul 11.
43. In vivo inhibition of angiogenesis by interleukin-13 gene therapy in a rat model of rheumatoid arthritis. Haas CS, etal., Arthritis Rheum. 2007 Aug;56(8):2535-48.
44. Release of B cell-activating factor of the TNF family in bronchoalveolar lavage from Behcet's disease with pulmonary involvement. Hamzaoui A, etal., Oxid Med Cell Longev. 2010 Mar-Apr;3(2):122-8.
45. Pulmonary T(H)2 response in Pseudomonas aeruginosa-infected patients with cystic fibrosis. Hartl D, etal., J Allergy Clin Immunol. 2006 Jan;117(1):204-11. Epub 2005 Nov 28.
46. Serum levels of tumor necrosis factor and interleukin-13 are elevated in patients with localized scleroderma. Hasegawa M, etal., Dermatology. 2003;207(2):141-7.
47. Elevated serum levels of interleukin 4 (IL-4), IL-10, and IL-13 in patients with systemic sclerosis. Hasegawa M, etal., J Rheumatol. 1997 Feb;24(2):328-32.
48. Increased expression of Interleukin-13 but not Interleukin-4 in cystic fibrosis patients. Hauber HP, etal., J Cyst Fibros. 2003 Dec;2(4):189-94.
49. Interleukin 13 cloning from DA rats. He XY, etal., Transplant Proc 1999 May;31(3):1572-3.
50. Genetic variants in inflammation-related genes are associated with radiation-induced toxicity following treatment for non-small cell lung cancer. Hildebrandt MA, etal., PLoS One. 2010 Aug 25;5(8):e12402.
51. Interleukin-13 gene polymorphisms confer the susceptibility of Japanese populations to Graves' disease. Hiromatsu Y, etal., J Clin Endocrinol Metab. 2005 Jan;90(1):296-301. Epub 2004 Oct 13.
52. Regulation of interleukin IL-4, IL-13, IL-10, and their downstream components in lipopolysaccharide-exposed rat lungs. Comparison of the constitutive expression between rats and humans. Hocke AC, etal., Cytokine. 2006 Feb 21;33(4):199-211. Epub 2006 Mar 7.
53. Identification and association of polymorphisms in the interleukin-13 gene with asthma and atopy in a Dutch population. Howard TD, etal., Am J Respir Cell Mol Biol. 2001 Sep;25(3):377-84.
54. [Study on the correlation of interleukin-13 polymorphism and susceptibility to chronic obstructive pulmonary disease in Chinese Han population] Hu RC, etal., Zhonghua Liu Xing Bing Xue Za Zhi. 2004 Jul;25(7):607-11.
55. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Huang C, etal., Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24.
56. Association of functional polymorphisms in promoter regions of IL5, IL6 and IL13 genes with development and prognosis of autoimmune thyroid diseases. Inoue N, etal., Clin Exp Immunol. 2011 Mar;163(3):318-23. doi: 10.1111/j.1365-2249.2010.04306.x. Epub 2011 Jan 14.
57. Th2 but not Th1 immune bias results in altered lung functions in a murine model of pulmonary Cryptococcus neoformans infection. Jain AV, etal., Infect Immun. 2009 Dec;77(12):5389-99. Epub 2009 Sep 14.
58. Association of gene polymorphisms of tumour necrosis factor-alpha and interleukin-13 with chronic obstructive pulmonary disease in Han nationality in Beijing. Jiang L, etal., Chin Med J (Engl). 2005 Apr 5;118(7):541-7.
59. IL-13 is sufficient for respiratory syncytial virus G glycoprotein-induced eosinophilia after respiratory syncytial virus challenge. Johnson TR, etal., J Immunol. 2003 Feb 15;170(4):2037-45.
60. Potent antitumor activity of IL-13 cytotoxin in human pancreatic tumors engineered to express IL-13 receptor alpha2 chain in vivo. Kawakami K, etal., Gene Ther. 2003 Jul;10(13):1116-28.
61. IL-13 is pivotal in the fibro-obliterative process of bronchiolitis obliterans syndrome. Keane MP, etal., J Immunol. 2007 Jan 1;178(1):511-9.
62. Decreased IL-10 and IL-13 production and increased CD44hi T cell recruitment contribute to Leishmania major immunity induced by non-persistent parasites. Kedzierski L, etal., Eur J Immunol. 2008 Nov;38(11):3090-100. doi: 10.1002/eji.200838423.
63. Combined effect of tumour necrosis factor-alpha and interleukin-13 polymorphisms on bronchial hyperresponsiveness in Korean children with asthma. Kim HB, etal., Clin Exp Allergy. 2008 May;38(5):774-80. Epub 2008 Mar 13.
64. Gene-gene interaction between IL-13 and IL-13Ralpha1 is associated with total IgE in Korean children with atopic asthma. Kim HB, etal., J Hum Genet. 2006;51(12):1055-62. Epub 2006 Sep 28.
65. Anti-tumor necrosis factor-alpha antibody treatment reduces pulmonary inflammation and methacholine hyper-responsiveness in a murine asthma model induced by house dust. Kim J, etal., Clin Exp Allergy. 2006 Jan;36(1):122-32.
66. Polymorphisms in the IL-13 and IL-4 receptor alpha genes and allergic rhinitis. Kim JJ, etal., Eur Arch Otorhinolaryngol. 2007 Apr;264(4):395-9. Epub 2006 Nov 8.
67. Topical delivery of interleukin-13 antisense oligonucleotides with cationic elastic liposome for the treatment of atopic dermatitis. Kim ST, etal., J Gene Med. 2009 Jan;11(1):26-37. doi: 10.1002/jgm.1268.
68. Direct effects of interleukin-13 on epithelial cells cause airway hyperreactivity and mucus overproduction in asthma. Kuperman DA, etal., Nat Med. 2002 Aug;8(8):885-9. Epub 2002 Jul 1.
69. Overexpression of interleukin-13 induces minimal-change-like nephropathy in rats. Lai KW, etal., J Am Soc Nephrol. 2007 May;18(5):1476-85. Epub 2007 Apr 11.
70. Cloning of rat interleukin-13 (IL-13) cDNA and analysis of IL-13 gene expression in experimental glomerulonephritis. Lakkis FG and Cruet EN, Biochem Biophys Res Commun 1993 Dec 15;197(2):612-8.
71. Serum levels of interleukins (IL)-4, IL-5, IL-13, and interferon-gamma in acute asthma. Lee YC, etal., J Asthma. 2001 Dec;38(8):665-71.
72. The effects of intraocular injection of interleukin-13 on endotoxin-induced uveitis in rats. Lemaitre C, etal., Invest Ophthalmol Vis Sci. 2001 Aug;42(9):2022-30.
73. Regulation of acute lung inflammatory injury by endogenous IL-13. Lentsch AB, etal., J Immunol. 1999 Jan 15;162(2):1071-6.
74. A polymorphism in the coding region of interleukin-13 gene is associated with atopy but not asthma in Chinese children. Leung TF, etal., Clin Exp Allergy. 2001 Oct;31(10):1515-21.
75. [Serum levels of IL-13 and TNF-alpha in children with Mycoplasma pneumoniae pneumonia] Li YF, etal., Zhongguo Dang Dai Er Ke Za Zhi. 2010 Apr;12(4):275-7.
76. Role of extracellular signal-regulated kinase in regulating expression of interleukin 13 in lymphocytes from an asthmatic rat model. Li YY, etal., Chin Med J (Engl). 2010 Jul;123(13):1715-9.
77. Il13 promoter (-1055) polymorphisms associated with chronic obstructive pulmonary disease in Taiwanese. Liu SF, etal., Exp Lung Res. 2009 Dec;35(10):807-16.
78. An IL13 coding region variant is associated with a high total serum IgE level and atopic dermatitis in the German multicenter atopy study (MAS-90). Liu X, etal., J Allergy Clin Immunol. 2000 Jul;106(1 Pt 1):167-70.
79. IL-13 induces connective tissue growth factor in rat hepatic stellate cells via TGF-beta-independent Smad signaling. Liu Y, etal., J Immunol. 2011 Sep 1;187(5):2814-23. Epub 2011 Jul 29.
80. Analysis of polymorphisms in olive pollen allergy: IL13, IL4RA, IL5 and ADRB2 genes. Llanes E, etal., Int Arch Allergy Immunol. 2009;148(3):228-38. doi: 10.1159/000161583. Epub 2008 Oct 10.
81. Cytokine-mediated inflammatory hyperalgesia limited by interleukin-13. Lorenzetti BB, etal., Eur Cytokine Netw. 2001 Apr-Jun;12(2):260-7.
82. Analysis of proinflammatory and anti-inflammatory cytokine serum concentrations in patients with multiple sclerosis by using a multiplexed immunoassay. Martins TB, etal., Am J Clin Pathol. 2011 Nov;136(5):696-704.
83. Expression and contribution of endogenous IL-13 in an experimental model of sepsis. Matsukawa A, etal., J Immunol. 2000 Mar 1;164(5):2738-44.
84. Upregulation of interleukin-13 and its receptor in a murine model of bleomycin-induced scleroderma. Matsushita M, etal., Int Arch Allergy Immunol. 2004 Dec;135(4):348-56. Epub 2004 Nov 24.
85. Rat ISS GO annotations from MGI mouse gene data--August 2006 MGD data from the GO Consortium
86. Interleukin-13 and -4 expression in the central airways of smokers with chronic bronchitis. Miotto D, etal., Eur Respir J. 2003 Oct;22(4):602-8.
87. Nicotine primarily suppresses lung Th2 but not goblet cell and muscle cell responses to allergens. Mishra NC, etal., J Immunol. 2008 Jun 1;180(11):7655-63.
88. Th2-biased immune responses are important in a murine model of chronic hypersensitivity pneumonitis. Mitaka K, etal., Int Arch Allergy Immunol. 2011;154(3):264-74. Epub 2010 Sep 21.
89. IL-13 is essential to the late-phase response in allergic rhinitis. Miyahara S, etal., J Allergy Clin Immunol. 2006 Nov;118(5):1110-6. Epub 2006 Aug 7.
90. Case-control study of IL13 polymorphisms, smoking, and rhinoconjunctivitis in Japanese women: the Kyushu Okinawa Maternal and Child Health Study. Miyake Y, etal., BMC Med Genet. 2011 Oct 25;12:143. doi: 10.1186/1471-2350-12-143.
91. Association of IL-13, RANTES, and leukotriene C4 synthase gene promoter polymorphisms with asthma and/or atopy in African Americans. Moissidis I, etal., Genet Med. 2005 Jul-Aug;7(6):406-10.
92. Increased level of interleukin-13, but not interleukin-4 and interferon-gamma in chronic rhinosinusitis with nasal polyps. Nabavi M, etal., Allergol Immunopathol (Madr). 2013 Aug 19. pii: S0301-0546(13)00192-4. doi: 10.1016/j.aller.2013.06.007.
93. Association of polymorphisms in genes encoding IL-4, IL-13 and their receptors with atopic dermatitis in a Korean population. Namkung JH, etal., Exp Dermatol. 2011 Nov;20(11):915-9. doi: 10.1111/j.1600-0625.2011.01357.x. Epub 2011 Sep 14.
94. Electronic Transfer of LocusLink and RefSeq Data NCBI rat LocusLink and RefSeq merged data July 26, 2002
95. Interleukin-13 promoter gene polymorphism -1112C/T is associated with the systemic form of mastocytosis. Nedoszytko B, etal., Allergy. 2009 Feb;64(2):287-94. doi: 10.1111/j.1398-9995.2008.01827.x.
96. Differential requirements for interleukin (IL)-4 and IL-13 in protein contact dermatitis induced by Anisakis. Nieuwenhuizen N, etal., Allergy. 2009 Sep;64(9):1309-18. doi: 10.1111/j.1398-9995.2009.02002.x. Epub 2009 Feb 18.
97. Mechanical stretch and angiotensin II increase interleukin-13 production and interleukin-13 receptor alpha2 expression in rat neonatal cardiomyocytes. Nishimura Y, etal., Circ J. 2008 Apr;72(4):647-53.
98. Relationship between pro-and anti-inflammatory cytokines profiles and some haematological parameters in some Cameroonians infected with Onchocerca volvulus. Nmorsi OP, etal., Asian Pac J Trop Med. 2012 Sep;5(9):713-7. doi: 10.1016/S1995-7645(12)60112-6.
99. OMIM Disease Annotation Pipeline OMIM Disease Annotation Pipeline
100. IL-13 Gene Polymorphisms are Associated With Rhinosinusitis and Eosinophilic Inflammation in Aspirin Intolerant Asthma. Palikhe NS, etal., Allergy Asthma Immunol Res. 2010 Apr;2(2):134-40. Epub 2010 Mar 24.
101. IL-13-induced oxidative stress via microglial NADPH oxidase contributes to death of hippocampal neurons in vivo. Park KW, etal., J Immunol. 2009 Oct 1;183(7):4666-74. doi: 10.4049/jimmunol.0803392. Epub 2009 Sep 14.
102. Interleukin-13 and its receptors in idiopathic interstitial pneumonia: clinical implications for lung function. Park SW, etal., J Korean Med Sci. 2009 Aug;24(4):614-20. Epub 2009 Jul 29.
103. Interleukin-13 expression in the nasal mucosa of perennial allergic rhinitis. Pawankar RU, etal., Am J Respir Crit Care Med. 1995 Dec;152(6 Pt 1):2059-67.
104. Th2 cytokine genotypes are associated with a milder form of primary Sjogren's syndrome. Pertovaara M, etal., Ann Rheum Dis. 2006 May;65(5):666-70. Epub 2005 Sep 15.
105. Expression of a functional IL-13Ralpha1 by rat B cells. Pierrot C, etal., Biochem Biophys Res Commun 2001 Oct 5;287(4):969-76.
106. KEGG Annotation Import Pipeline Pipeline to import KEGG annotations from KEGG into RGD
107. SMPDB Annotation Import Pipeline Pipeline to import SMPDB annotations from SMPDB into RGD
108. Eosinophils and type 2 cytokine signaling in macrophages orchestrate development of functional beige fat. Qiu Y, etal., Cell. 2014 Jun 5;157(6):1292-308. doi: 10.1016/j.cell.2014.03.066.
109. GOA pipeline RGD automated data pipeline
110. ClinVar Automated Import and Annotation Pipeline RGD automated import pipeline for ClinVar variants, variant-to-disease annotations and gene-to-disease annotations
111. Data Import for Chemical-Gene Interactions RGD automated import pipeline for gene-chemical interactions
112. LHRH antagonist Cetrorelix reduces prostate size and gene expression of proinflammatory cytokines and growth factors in a rat model of benign prostatic hyperplasia. Rick FG, etal., Prostate. 2011 May 15;71(7):736-47. doi: 10.1002/pros.21289. Epub 2010 Oct 13.
113. Differential expression of interleukins IL-13 and IL-15 in normal ovarian tissue and ovarian carcinomas. Ripley D, etal., Gynecol Oncol. 2004 Mar;92(3):761-8.
114. Potential role of IL-13 in neuroprotection and cortical excitability regulation in multiple sclerosis. Rossi S, etal., Mult Scler. 2011 Nov;17(11):1301-12. doi: 10.1177/1352458511410342. Epub 2011 Jun 15.
115. Effects of the sigma-1 receptor agonist 1-(3,4-dimethoxyphenethyl)-4-(3-phenylpropyl)-piperazine dihydro-chloride on inflammation after stroke. Ruscher K, etal., PLoS One. 2012;7(9):e45118. doi: 10.1371/journal.pone.0045118. Epub 2012 Sep 18.
116. Interleukin 4 and 13 participation in mycobacterial (type-1) and schistosomal (type-2) antigen-elicited pulmonary granuloma formation: multiparameter analysis of cellular recruitment, chemokine expression and cytokine networks. Ruth JH, etal., Cytokine. 2000 May;12(5):432-44.
117. Increased sputum and bronchial biopsy IL-13 expression in severe asthma. Saha SK, etal., J Allergy Clin Immunol. 2008 Mar;121(3):685-91.
118. Elastase- and LPS-exposed mice display altered responses to rhinovirus infection. Sajjan U, etal., Am J Physiol Lung Cell Mol Physiol. 2009 Nov;297(5):L931-44. Epub 2009 Sep 11.
119. Adenovirus-mediated interleukin-13 gene therapy attenuates acute kidney allograft injury. Sandovici M, etal., J Gene Med. 2007 Dec;9(12):1024-32.
120. Systemic gene therapy with interleukin-13 attenuates renal ischemia-reperfusion injury. Sandovici M, etal., Kidney Int. 2008 Jun;73(12):1364-73. Epub 2008 Mar 19.
121. Type 2 cytokine gene activation and its relationship to extent of disease in patients with tuberculosis. Seah GT, etal., J Infect Dis. 2000 Jan;181(1):385-9.
122. IL-4/IL-13 suppress excessive neutrophil infiltration and hepatocyte damage during acute murine schistosomiasis japonica. Seki T, etal., Infect Immun. 2011 Oct 28.
123. IL-13 gene polymorphisms and their association with atopic asthma and rhinitis in Pakistani patients. Shazia M, etal., Iran J Allergy Asthma Immunol. 2013 Aug 28;12(4):391-6.
124. Novel role of IL-13 in fibrosis induced by nonalcoholic steatohepatitis and its amelioration by IL-13R-directed cytotoxin in a rat model. Shimamura T, etal., J Immunol. 2008 Oct 1;181(7):4656-65.
125. IL-4-induced selective clearance of oligomeric beta-amyloid peptide(1-42) by rat primary type 2 microglia. Shimizu E, etal., J Immunol. 2008 Nov 1;181(9):6503-13.
126. IL-13 promotes the proliferation of rat pancreatic stellate cells through the suppression of NF-kappaB/TGF-beta1 pathway. Shinozaki S, etal., Biochem Biophys Res Commun. 2010 Feb 26;393(1):61-5. Epub 2010 Jan 25.
127. IL-13-mediated gender difference in susceptibility to autoimmune encephalomyelitis. Sinha S, etal., J Immunol. 2008 Feb 15;180(4):2679-85.
128. Interleukin-13 in autoimmune rheumatic diseases: relationship with the autoantibody profile. Spadaro A, etal., Clin Exp Rheumatol. 2002 Mar-Apr;20(2):213-6.
129. Interleukin 13 expression in the primary breast cancer tumour tissue. Srabovici N, etal., Biochem Med (Zagreb). 2011;21(2):131-8.
130. A novel rat model to determine interaction between reflux oesophagitis and bronchial asthma. Sugawa T, etal., Gut. 2008 May;57(5):575-81. Epub 2008 Jan 25.
131. Mizoribine provides effective treatment of sequential histological change of arteritis and reduction of inflammatory cytokines and chemokines in an animal model of Kawasaki disease. Takahashi K, etal., Pediatr Rheumatol Online J. 2011 Sep 29;9(1):30.
132. Interleukin-13 prevents diaphragm muscle deterioration in a septic animal model. Takahashi Y, etal., Tohoku J Exp Med. 1999 Nov;189(3):191-202.
133. T helper and regulatory T cell cytokine profile in active, stable and narrow band ultraviolet B treated generalized vitiligo. Tembhre MK, etal., Clin Chim Acta. 2013 Sep 23;424:27-32. doi: 10.1016/j.cca.2013.05.005. Epub 2013 May 13.
134. P-selectin inhibition decreases post-thrombotic vein wall fibrosis in a rat model. Thanaporn P, etal., Surgery. 2003 Aug;134(2):365-71.
135. Adenovirus IL-13-induced airway disease in mice: a corticosteroid-resistant model of severe asthma. Therien AG, etal., Am J Respir Cell Mol Biol. 2008 Jul;39(1):26-35. Epub 2008 Feb 7.
136. Molecular characterization of inflammatory genes in sentinel and nonsentinel nodes in melanoma. Torisu-Itakura H, etal., Clin Cancer Res. 2007 Jun 1;13(11):3125-32.
137. Relation between serum IL-4, IL-13 and IFN-gamma levels and recurrence of wheezing episodes in infants with acute bronchiolitis. Uzuner N, etal., Pediatr Allergy Immunol. 2008 Nov;19(7):648-51. Epub 2008 Feb 27.
138. Interleukin-4 and -13 promote basolateral secretion of H(+) and cathepsin L by glomerular epithelial cells. Van Den Berg JG, etal., Am J Physiol Renal Physiol. 2002 Jan;282(1):F26-33.
139. Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases Wang C and Pang BS, Zhonghua Jie He He Hu Xi Za Zhi. 2003 Oct;26(10):586-9.
140. A common IL-13 Arg130Gln single nucleotide polymorphism among Chinese atopy patients with allergic rhinitis. Wang M, etal., Hum Genet. 2003 Oct;113(5):387-90. Epub 2003 Aug 20.
141. Therapeutic efficacy of milrinone in the management of enterovirus 71-induced pulmonary edema. Wang SM, etal., Pediatr Pulmonol. 2005 Mar;39(3):219-23.
142. Increased expression of non-interleukin-2 T cell growth factors and their implications during liver allograft rejection in rats. Wang WL, etal., J Gastroenterol Hepatol. 2007 Jul;22(7):1141-7. Epub 2007 May 27.
143. [Correlation of IL-4 and IL-13 gene polymorphisms with asthma and total serum IgE levels] Wang XH, etal., Zhonghua Jie He He Hu Xi Za Zhi. 2009 Mar;32(3):161-4.
144. Interleukin-13-dependent bronchial hyper-responsiveness following isolated upper-airway allergen challenge in a murine model of allergic rhinitis and asthma. Wang Y and McCusker CT, Clin Exp Allergy. 2005 Aug;35(8):1104-11.
145. Endogenous regulation of the acute inflammatory response. Ward PA and Lentsch AB, Mol Cell Biochem 2002 May-Jun;234-235(1-2):225-8.
146. Bleomycin and IL-1beta-mediated pulmonary fibrosis is IL-17A dependent. Wilson MS, etal., J Exp Med. 2010 Mar 15;207(3):535-52. Epub 2010 Feb 22.
147. Interleukin-13 gene therapy reduces inflammation, vascularization, and bony destruction in rat adjuvant-induced arthritis. Woods JM, etal., Hum Gene Ther. 2002 Feb 10;13(3):381-93.
148. Association between IL-13 gene polymorphism and asthma in Han nationality in Hubei Chinese population. Xi D, etal., J Huazhong Univ Sci Technolog Med Sci. 2004;24(3):219-22.
149. [Interleukin-4 and interleukin-13 concentrations in bronchoalveolar lavage fluid in neonates with respiratory distress syndrome and concurrent ventilator-associated pneumonia] Xia YF, etal., Zhongguo Dang Dai Er Ke Za Zhi. 2009 Aug;11(8):645-8.
150. Polymorphic variants of interleukin-13 R130Q, interleukin-4 T589C, interleukin-4RA I50V, and interleukin-4RA Q576R in allergic rhinitis: A pilot study. Yadav A, etal., Allergy Rhinol (Providence). 2012;3(1):e35-40. doi: 10.2500/ar.2012.3.0022. Epub 2012 May 18.
151. Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19. Yang Y, etal., J Allergy Clin Immunol. 2020 Apr 29. pii: S0091-6749(20)30576-5. doi: 10.1016/j.jaci.2020.04.027.
152. Impact of T-cell receptor Vbeta haplotypes on the development of dermatitis in DS-Nh mice: synergistic production of interleukin-13 caused by staphylococcal enterotoxin C and peptide glycans from Staphylococcus aureus. Yoshioka T, etal., Immunology. 2007 May;121(1):51-61. Epub 2007 Feb 20.
153. [Studies on the expression of mRNA of anti- and pro-inflammatory cytokines in acute lung injury induced by lipopolysaccharide in rat] Zhang Q, etal., Zhongguo Wei Zhong Bing Ji Jiu Yi Xue. 2004 Oct;16(10):585-8.
154. Effect of tea polyphenol on cytokine gene expression in rats with alcoholic liver disease. Zhang XG, etal., Hepatobiliary Pancreat Dis Int. 2006 May;5(2):268-72.
155. Inducible targeting of IL-13 to the adult lung causes matrix metalloproteinase- and cathepsin-dependent emphysema. Zheng T, etal., J Clin Invest. 2000 Nov;106(9):1081-93.
156. IL13 variants are associated with total serum IgE and early sensitization to food allergens in children with atopic dermatitis. Zitnik SE, etal., Pediatr Allergy Immunol. 2009 Sep;20(6):551-5. doi: 10.1111/j.1399-3038.2008.00815.x. Epub 2009 Jun 10.
157. Interactive effect of STAT6 and IL13 gene polymorphisms on eczema status: results from a longitudinal and a cross-sectional study. Ziyab AH, etal., BMC Med Genet. 2013 Jul 2;14:67. doi: 10.1186/1471-2350-14-67.
158. IL-13 induces esophageal remodeling and gene expression by an eosinophil-independent, IL-13R alpha 2-inhibited pathway. Zuo L, etal., J Immunol. 2010 Jul 1;185(1):660-9. Epub 2010 Jun 11.
Additional References at PubMed
PMID:11737071   PMID:12574355   PMID:12919086   PMID:15042582   PMID:15087456   PMID:15240714   PMID:15647285   PMID:15944273   PMID:15961726   PMID:16034134   PMID:16275384   PMID:16949315  
PMID:17082577   PMID:17723228   PMID:18644231   PMID:18792410   PMID:18997793   PMID:19120067   PMID:19666510   PMID:19783789   PMID:19841166   PMID:20041150   PMID:20221786   PMID:20500673  
PMID:20522789   PMID:21460847   PMID:23881867   PMID:26591203   PMID:26722390   PMID:30353658   PMID:30634164   PMID:31934720   PMID:33801783  


Genomics

Comparative Map Data
Il13
(Rattus norvegicus - Norway rat)
Rat AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
mRatBN7.21037,790,130 - 37,792,687 (-)NCBImRatBN7.2mRatBN7.2
mRatBN7.2 Ensembl1037,790,130 - 37,792,737 (-)EnsemblmRatBN7.2 Ensembl
UTH_Rnor_SHR_Utx1042,482,076 - 42,484,637 (-)NCBIRnor_SHR
UTH_Rnor_SHRSP_BbbUtx_1.01041,972,140 - 41,974,701 (-)NCBIRnor_SHRSP
UTH_Rnor_WKY_Bbb_1.01037,475,862 - 37,478,423 (-)NCBIRnor_WKY
Rnor_6.01038,982,909 - 38,985,466 (-)NCBIRnor6.0Rnor_6.0rn6Rnor6.0
Rnor_6.0 Ensembl1038,982,909 - 38,985,466 (-)EnsemblRnor6.0rn6Rnor6.0
Rnor_5.01038,764,639 - 38,767,196 (-)NCBIRnor5.0Rnor_5.0rn5Rnor5.0
RGSC_v3.41039,093,512 - 39,096,069 (-)NCBIRGSC3.4RGSC_v3.4rn4RGSC3.4
RGSC_v3.11039,102,758 - 39,105,316 (-)NCBI
Celera1037,134,342 - 37,136,897 (-)NCBICelera
Cytogenetic Map10q22NCBI
IL13
(Homo sapiens - human)
Human AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
GRCh385132,656,522 - 132,661,110 (+)NCBIGRCh38GRCh38hg38GRCh38
GRCh38.p13 Ensembl5132,656,263 - 132,661,110 (+)EnsemblGRCh38hg38GRCh38
GRCh375131,992,214 - 131,996,802 (+)NCBIGRCh37GRCh37hg19GRCh37
Build 365132,021,764 - 132,024,700 (+)NCBINCBI36Build 36hg18NCBI36
Build 345132,021,763 - 132,024,700NCBI
Celera5128,123,995 - 128,126,931 (+)NCBICelera
Cytogenetic Map5q31.1NCBI
HuRef5127,186,169 - 127,189,105 (+)NCBIHuRef
CHM1_15131,427,162 - 131,430,098 (+)NCBICHM1_1
T2T-CHM13v2.05133,176,323 - 133,180,911 (+)NCBIT2T-CHM13v2.0
Il13
(Mus musculus - house mouse)
Mouse AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
GRCm391153,522,150 - 53,525,529 (-)NCBIGRCm39GRCm39mm39
GRCm39 Ensembl1153,522,151 - 53,525,529 (-)EnsemblGRCm39 Ensembl
GRCm381153,631,323 - 53,634,702 (-)NCBIGRCm38GRCm38mm10GRCm38
GRCm38.p6 Ensembl1153,631,324 - 53,634,702 (-)EnsemblGRCm38mm10GRCm38
MGSCv371153,444,825 - 53,448,204 (-)NCBIGRCm37MGSCv37mm9NCBIm37
MGSCv361153,474,747 - 53,478,125 (-)NCBIMGSCv36mm8
Celera1158,210,849 - 58,214,228 (-)NCBICelera
Cytogenetic Map11B1.3NCBI
cM Map1131.98NCBI
Il13
(Chinchilla lanigera - long-tailed chinchilla)
Chinchilla AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
ChiLan1.0NW_0049554084,046,406 - 4,049,795 (+)NCBIChiLan1.0ChiLan1.0
IL13
(Pan paniscus - bonobo/pygmy chimpanzee)
Bonobo AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
PanPan1.15134,235,788 - 134,240,548 (+)NCBIpanpan1.1PanPan1.1panPan2
PanPan1.1 Ensembl5134,235,788 - 134,240,548 (+)Ensemblpanpan1.1panPan2
Mhudiblu_PPA_v05128,073,863 - 128,078,453 (+)NCBIMhudiblu_PPA_v0Mhudiblu_PPA_v0panPan3
IL13
(Canis lupus familiaris - dog)
Dog AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
CanFam3.11120,957,870 - 20,961,391 (+)NCBICanFam3.1CanFam3.1canFam3CanFam3.1
CanFam3.1 Ensembl1120,958,464 - 20,961,388 (+)EnsemblCanFam3.1canFam3CanFam3.1
Dog10K_Boxer_Tasha1119,759,917 - 19,762,847 (+)NCBIDog10K_Boxer_Tasha
ROS_Cfam_1.01121,744,389 - 21,747,318 (+)NCBIROS_Cfam_1.0
ROS_Cfam_1.0 Ensembl1121,744,389 - 21,747,315 (+)EnsemblROS_Cfam_1.0 Ensembl
UMICH_Zoey_3.11120,462,871 - 20,465,798 (+)NCBIUMICH_Zoey_3.1
UNSW_CanFamBas_1.01120,310,464 - 20,313,371 (+)NCBIUNSW_CanFamBas_1.0
UU_Cfam_GSD_1.01120,952,917 - 20,955,847 (+)NCBIUU_Cfam_GSD_1.0
Il13
(Ictidomys tridecemlineatus - thirteen-lined ground squirrel)
Squirrel AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
HiC_Itri_2NW_024407213115,527,018 - 115,529,671 (-)NCBIHiC_Itri_2
SpeTri2.0 EnsemblNW_0049366472,530,491 - 2,532,373 (-)EnsemblSpeTri2.0
SpeTri2.0NW_0049366472,529,933 - 2,532,503 (-)NCBISpeTri2.0SpeTri2.0SpeTri2.0
IL13
(Sus scrofa - pig)
Pig AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
Sscrofa11.1 Ensembl2134,972,623 - 134,975,093 (+)EnsemblSscrofa11.1susScr11Sscrofa11.1
Sscrofa11.12134,972,099 - 134,976,672 (+)NCBISscrofa11.1Sscrofa11.1susScr11Sscrofa11.1
Sscrofa10.22140,441,025 - 140,444,068 (+)NCBISscrofa10.2Sscrofa10.2susScr3
IL13
(Chlorocebus sabaeus - green monkey)
Green Monkey AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
ChlSab1.12335,475,762 - 35,479,419 (+)NCBIChlSab1.1ChlSab1.1chlSab2
ChlSab1.1 Ensembl2335,476,490 - 35,478,869 (+)EnsemblChlSab1.1ChlSab1.1 EnsemblchlSab2
Vero_WHO_p1.0NW_02366603442,463,847 - 42,466,277 (-)NCBIVero_WHO_p1.0Vero_WHO_p1.0
Il13
(Heterocephalus glaber - naked mole-rat)
Naked Mole-rat AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
HetGla_female_1.0 EnsemblNW_00462473339,428,095 - 39,429,843 (-)EnsemblHetGla_female_1.0HetGla_female_1.0 EnsemblhetGla2
HetGla 1.0NW_00462473339,427,189 - 39,430,019 (-)NCBIHetGla_female_1.0HetGla 1.0hetGla2

Variants

.
Variants in Il13
6 total Variants
miRNA Target Status

Predicted Target Of
Summary Value
Count of predictions:51
Count of miRNA genes:44
Interacting mature miRNAs:49
Transcripts:ENSRNOT00000010121
Prediction methods:Miranda, Rnahybrid, Targetscan
Result types:miRGate_prediction

The detailed report is available here: Full Report CSV TAB Printer

miRNA Target Status data imported from miRGate (http://mirgate.bioinfo.cnio.es/).
For more information about miRGate, see PMID:25858286 or access the full paper here.


QTLs in Region (mRatBN7.2)
The following QTLs overlap with this region.    Full Report CSV TAB Printer Gviewer
RGD IDSymbolNameLODP ValueTraitSub TraitChrStartStopSpecies
634327Hc4Hypercalciuria QTL 42.4urine calcium amount (VT:0002985)urine calcium excretion rate (CMO:0000763)10138328221Rat
7411611Foco17Food consumption QTL 1718.70.001eating behavior trait (VT:0001431)feed conversion ratio (CMO:0001312)10142315980Rat
70223Bp57Blood pressure QTL 575arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)10180676123Rat
10401803Kidm50Kidney mass QTL 50kidney mass (VT:0002707)both kidneys wet weight (CMO:0000085)1041834445418344Rat
631554Bp133Blood pressure QTL 1330.005arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)1074336463851208Rat
2313064Bmd71Bone mineral density QTL 710.90.0001tibia mineral mass (VT:1000283)cortical volumetric bone mineral density (CMO:0001730)10538701450387014Rat
2313066Bss63Bone structure and strength QTL 631.40.0001tibia strength trait (VT:1000284)bone polar moment of inertia (CMO:0001558)10538701450387014Rat
2313081Bss64Bone structure and strength QTL 641.30.0001tibia strength trait (VT:1000284)tibia total energy absorbed before break (CMO:0001736)10538701450387014Rat
2313095Bss62Bone structure and strength QTL 621.50.0001tibia size trait (VT:0100001)tibia midshaft cross-sectional area (CMO:0001717)10538701450387014Rat
2313104Bss61Bone structure and strength QTL 610.90.0001tibia area (VT:1000281)tibia midshaft cross-sectional area (CMO:0001717)10538701450387014Rat
2298544Neuinf9Neuroinflammation QTL 94.6nervous system integrity trait (VT:0010566)spinal cord complement component 1, q subcomponent, B chain mRNA level (CMO:0002126)10580199062146030Rat
8662860Vetf10Vascular elastic tissue fragility QTL 10artery integrity trait (VT:0010639)number of ruptures of the internal elastic lamina of the abdominal aorta and iliac arteries (CMO:0002562)10615418273453136Rat
61427Cia16Collagen induced arthritis QTL 163.2joint integrity trait (VT:0010548)joint inflammation composite score (CMO:0000919)10635789696121100Rat
1578761Stresp21Stress response QTL 213.3thymus mass (VT:0004954)thymus wet weight (CMO:0000855)10637574651375746Rat
2303118Mamtr7Mammary tumor resistance QTL 70.003mammary gland integrity trait (VT:0010552)mammary tumor growth rate (CMO:0000344)109658275104670812Rat
9590310Scort19Serum corticosterone level QTL 196.30.001blood corticosterone amount (VT:0005345)plasma corticosterone level (CMO:0001173)101147401056474010Rat
9590268Scort13Serum corticosterone level QTL 133.260.001blood corticosterone amount (VT:0005345)plasma corticosterone level (CMO:0001173)101147401056474010Rat
9589136Insul27Insulin level QTL 2710.460.001blood insulin amount (VT:0001560)plasma insulin level (CMO:0000342)101147401056474010Rat
2301967Cm73Cardiac mass QTL 734.55heart left ventricle mass (VT:0007031)heart left ventricle weight to body weight ratio (CMO:0000530)101448701189062041Rat
631268Cia21Collagen induced arthritis QTL 213.1joint integrity trait (VT:0010548)joint inflammation composite score (CMO:0000919)1014487011104060283Rat
2316949Gluco60Glucose level QTL 603.7blood glucose amount (VT:0000188)blood glucose level (CMO:0000046)1014487011107057807Rat
1354587Kidm21Kidney mass QTL 213.3kidney mass (VT:0002707)right kidney wet weight (CMO:0000082)101502851360430477Rat
631564Apr3Acute phase response QTL 33.9blood interleukin-6 amount (VT:0008595)plasma interleukin-6 level (CMO:0001927)101527595560275955Rat
6893350Bw99Body weight QTL 990.870.16body mass (VT:0001259)body weight (CMO:0000012)11590666560906665Rat
6893352Bw100Body weight QTL 1000.330.6body mass (VT:0001259)body weight (CMO:0000012)11590666560906665Rat
631532Cm50Cardiac mass QTL 506.6heart mass (VT:0007028)calculated heart weight (CMO:0000073)101790711351786432Rat
1598852Anxrr19Anxiety related response QTL 195.07body movement coordination trait (VT:0005424)number of rearing movements in an experimental apparatus (CMO:0001752)101816784163167841Rat
2313055Bw96Body weight QTL 963.60.0001body mass (VT:0001259)body weight (CMO:0000012)101960648364606483Rat
2313087Bmd80Bone mineral density QTL 803.20.0001tibia mineral mass (VT:1000283)total volumetric bone mineral density (CMO:0001728)101960648364606483Rat
1554317Bmd4Bone mineral density QTL 49.40.0001lumbar vertebra mineral mass (VT:0010511)volumetric bone mineral density (CMO:0001553)101981604299406971Rat
1581497Esta1Estrogen-induced thymic atrophy QTL 1thymus mass (VT:0004954)thymus wet weight (CMO:0000855)102132980561345413Rat
724556Pur2Proteinuria QTL 25.5urine protein amount (VT:0005160)urine protein level (CMO:0000591)102242750090627625Rat
61354Pia10Pristane induced arthritis QTL 100.01joint integrity trait (VT:0010548)joint inflammation composite score (CMO:0000919)1023444813104060283Rat
631267Cia20Collagen induced arthritis QTL 203.2joint integrity trait (VT:0010548)joint inflammation composite score (CMO:0000919)1023444813104060283Rat
61325Aia5Adjuvant induced arthritis QTL 50.01joint integrity trait (VT:0010548)joint inflammation composite score (CMO:0000919)1023444813104060283Rat
70224Eae3Experimental allergic encephalomyelitis QTL 34.1nervous system integrity trait (VT:0010566)experimental autoimmune encephalomyelitis incidence/prevalence measurement (CMO:0001046)102652195761345413Rat
1298069Bp168Blood pressure QTL 1685.5blood pressure trait (VT:0000183)systolic blood pressure (CMO:0000004)102652195798003205Rat
631542Bp82Blood pressure QTL 826.8arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)102652195798952741Rat
2300171Bmd58Bone mineral density QTL 584.90.0001lumbar vertebra mineral mass (VT:0010511)volumetric bone mineral density (CMO:0001553)102694462871944628Rat
10402859Bp381Blood pressure QTL 3810.002arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)102760646872606468Rat
2292441Bp308Blood pressure QTL 308arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)102760646872606468Rat
724527Bp148Blood pressure QTL 1480.0001arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)102845313673453136Rat
1600371Mcs21Mammary carcinoma susceptibility QTL 213mammary gland integrity trait (VT:0010552)mammary tumor growth rate (CMO:0000344)102887565052200160Rat
1331762Rf40Renal function QTL 403.873kidney blood vessel physiology trait (VT:0100012)absolute change in renal vascular resistance (CMO:0001900)102929950464155584Rat
1331791Cm31Cardiac mass QTL 313.84606heart mass (VT:0007028)heart wet weight (CMO:0000069)1029299504107211142Rat
631557Bp136Blood pressure QTL 1360.003arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)103063205375632053Rat
1576311Pia26Pristane induced arthritis QTL 26joint integrity trait (VT:0010548)joint inflammation composite score (CMO:0000919)103122402675632053Rat
1578779Tcas10Tongue tumor susceptibility QTL 103.12tongue integrity trait (VT:0010553)number of squamous cell tumors of the tongue with diameter greater than 3 mm (CMO:0001950)103129743976297439Rat
1576319Cia29Collagen induced arthritis QTL 29joint integrity trait (VT:0010548)joint inflammation composite score (CMO:0000919)103397392178973921Rat
61332Eau3Experimental allergic uveoretinitis QTL 30.004uvea integrity trait (VT:0010551)experimental autoimmune uveitis score (CMO:0001504)103449055945579777Rat
1354614Hpcl1Hepatic cholesterol level QTL 13.3liver cholesterol amount (VT:0010498)liver cholesterol level (CMO:0001597)103539226751793994Rat
1358897Stresp6Stress response QTL 64.170.022blood norepinephrine amount (VT:0005663)plasma norepinephrine level (CMO:0001010)103539226764155584Rat
61441Btemp1Thermal response to stress QTL 14body temperature trait (VT:0005535)core body temperature (CMO:0001036)103539245763642539Rat
2317042Aia20Adjuvant induced arthritis QTL 203.38joint integrity trait (VT:0010548)right rear ankle joint diameter (CMO:0002150)103756507982565079Rat
2317043Aia7Adjuvant induced arthritis QTL 73.82joint integrity trait (VT:0010548)left rear ankle joint diameter (CMO:0002149)103756507982565079Rat


Expression


RNA-SEQ Expression
High: > 1000 TPM value   Medium: Between 11 and 1000 TPM
Low: Between 0.5 and 10 TPM   Below Cutoff: < 0.5 TPM

alimentary part of gastrointestinal system endocrine system exocrine system hemolymphoid system hepatobiliary system integumental system musculoskeletal system nervous system reproductive system respiratory system appendage
High
Medium
Low 7 1 6 1 1
Below cutoff 2 1 4 1 1 1 6 2 1

Sequence


Reference Sequences
RefSeq Acc Id: ENSRNOT00000010121   ⟹   ENSRNOP00000010121
RefSeq Status:
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
mRatBN7.2 Ensembl1037,790,130 - 37,792,737 (-)Ensembl
Rnor_6.0 Ensembl1038,982,909 - 38,985,466 (-)Ensembl
RefSeq Acc Id: NM_053828   ⟹   NP_446280
RefSeq Status: PROVISIONAL
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
mRatBN7.21037,790,130 - 37,792,687 (-)NCBI
Rnor_6.01038,982,909 - 38,985,466 (-)NCBI
Rnor_5.01038,764,639 - 38,767,196 (-)NCBI
RGSC_v3.41039,093,512 - 39,096,069 (-)RGD
Celera1037,134,342 - 37,136,897 (-)RGD
Sequence:
Protein Sequences
Protein RefSeqs NP_446280 (Get FASTA)   NCBI Sequence Viewer  
GenBank Protein AAA16478 (Get FASTA)   NCBI Sequence Viewer  
  EDM04394 (Get FASTA)   NCBI Sequence Viewer  
  P42203 (Get FASTA)   NCBI Sequence Viewer  
Reference Sequences
RefSeq Acc Id: NP_446280   ⟸   NM_053828
- Peptide Label: precursor
- UniProtKB: P42203 (UniProtKB/Swiss-Prot)
- Sequence:
RefSeq Acc Id: ENSRNOP00000010121   ⟸   ENSRNOT00000010121

Protein Structures
Name Modeler Protein Id AA Range Protein Structure
AF-P42203-F1-model_v2 AlphaFold P42203 1-131 view protein structure

Transcriptome

eQTL   View at Phenogen
WGCNA   View at Phenogen
Tissue/Strain Expression   View at Phenogen


Additional Information

Database Acc Id Source(s)
AGR Gene RGD:68949 AgrOrtholog
BioCyc Gene G2FUF-25135 BioCyc
Ensembl Genes ENSRNOG00000007652 Ensembl, ENTREZGENE, UniProtKB/Swiss-Prot
Ensembl Protein ENSRNOP00000010121 ENTREZGENE, UniProtKB/Swiss-Prot
Ensembl Transcript ENSRNOT00000010121 ENTREZGENE, UniProtKB/Swiss-Prot
Gene3D-CATH 1.20.1250.10 UniProtKB/Swiss-Prot
InterPro 4_helix_cytokine-like_core UniProtKB/Swiss-Prot
  IL-13 UniProtKB/Swiss-Prot
  IL-4/IL-13 UniProtKB/Swiss-Prot
  IL-4/IL-13_CS UniProtKB/Swiss-Prot
KEGG Report rno:116553 UniProtKB/Swiss-Prot
NCBI Gene 116553 ENTREZGENE
Pfam IL13 UniProtKB/Swiss-Prot
PharmGKB IL13 RGD
PhenoGen Il13 PhenoGen
PRINTS INTRLEUKIN13 UniProtKB/Swiss-Prot
PROSITE INTERLEUKIN_4_13 UniProtKB/Swiss-Prot
SMART IL4_13 UniProtKB/Swiss-Prot
Superfamily-SCOP SSF47266 UniProtKB/Swiss-Prot
UniProt IL13_RAT UniProtKB/Swiss-Prot, ENTREZGENE


Nomenclature History
Date Current Symbol Current Name Previous Symbol Previous Name Description Reference Status
2002-06-10 Il13  interleukin 13      Symbol and Name status set to approved 70586 APPROVED

RGD Curation Notes
Note Type Note Reference
gene_homology has 74% and 87% sequence identity with the coding regions of human and mouse IL-13 cDNA 729020
gene_process may function in regulating inflammatory and immune responses 61509